Denali Therapeutics IncNASDAQ:DNLI
- LAST PRICE21.3000
- TODAY'S CHANGE (%)-0.4400 (-2.0239%)
- Bid / Lots20.6000/ 4
- Ask / Lots22.2500/ 1
- Open / Previous Close21.9700 / 21.7400
- Day Range
- 52 Week Range
- Volume491,640
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | DNLI |
|---|---|---|
| 09:32 ET | 3866 | 21.87 |
| 09:34 ET | 700 | 21.79 |
| 09:36 ET | 700 | 22 |
| 09:38 ET | 3646 | 22.09 |
| 09:39 ET | 600 | 22.03 |
| 09:41 ET | 1845 | 22.12 |
| 09:43 ET | 200 | 22.14 |
| 09:45 ET | 431 | 22.19 |
| 09:48 ET | 3194 | 22.13 |
| 09:50 ET | 300 | 22.14 |
| 09:52 ET | 800 | 22.2 |
| 09:54 ET | 1500 | 22.13 |
| 09:56 ET | 2132 | 22.04 |
| 09:57 ET | 3000 | 22.025 |
| 09:59 ET | 300 | 22.025 |
| 10:01 ET | 2017 | 22.145 |
| 10:03 ET | 2188 | 22.09 |
| 10:06 ET | 2600 | 22.04 |
| 10:08 ET | 3633 | 22 |
| 10:10 ET | 200 | 21.97 |
| 10:12 ET | 1131 | 21.97 |
| 10:14 ET | 1400 | 22.03 |
| 10:15 ET | 1507 | 22.08 |
| 10:17 ET | 2500 | 22.11 |
| 10:19 ET | 881 | 22.115 |
| 10:21 ET | 5300 | 22.15 |
| 10:24 ET | 1400 | 22.17 |
| 10:26 ET | 300 | 22.22 |
| 10:28 ET | 2830 | 22.11 |
| 10:30 ET | 100 | 22.02 |
| 10:32 ET | 1659 | 21.985 |
| 10:33 ET | 301 | 22 |
| 10:35 ET | 721 | 22.04 |
| 10:37 ET | 2501 | 21.975 |
| 10:42 ET | 644 | 21.9 |
| 10:44 ET | 428 | 21.81 |
| 10:46 ET | 400 | 21.77 |
| 10:48 ET | 1378 | 21.71 |
| 10:50 ET | 600 | 21.69 |
| 10:51 ET | 400 | 21.69 |
| 10:53 ET | 1379 | 21.6 |
| 10:55 ET | 1066 | 21.59 |
| 10:57 ET | 543 | 21.55 |
| 11:00 ET | 1000 | 21.47 |
| 11:02 ET | 2445 | 21.5 |
| 11:04 ET | 400 | 21.5 |
| 11:08 ET | 1950 | 21.46 |
| 11:09 ET | 2000 | 21.47 |
| 11:11 ET | 703 | 21.485 |
| 11:13 ET | 200 | 21.495 |
| 11:15 ET | 2320 | 21.5 |
| 11:18 ET | 600 | 21.53 |
| 11:22 ET | 306 | 21.53 |
| 11:24 ET | 879 | 21.52 |
| 11:26 ET | 2400 | 21.495 |
| 11:27 ET | 500 | 21.45 |
| 11:29 ET | 989 | 21.4407 |
| 11:31 ET | 1326 | 21.435 |
| 11:33 ET | 300 | 21.4 |
| 11:36 ET | 1315 | 21.395 |
| 11:38 ET | 2020 | 21.375 |
| 11:40 ET | 600 | 21.405 |
| 11:42 ET | 200 | 21.41 |
| 11:45 ET | 1200 | 21.38 |
| 11:47 ET | 1742 | 21.36 |
| 11:49 ET | 1461 | 21.33 |
| 11:51 ET | 240 | 21.32 |
| 11:54 ET | 100 | 21.31 |
| 11:56 ET | 400 | 21.29 |
| 12:00 ET | 400 | 21.29 |
| 12:02 ET | 400 | 21.3 |
| 12:03 ET | 600 | 21.3 |
| 12:05 ET | 1411 | 21.325 |
| 12:07 ET | 1600 | 21.39 |
| 12:09 ET | 100 | 21.385 |
| 12:12 ET | 300 | 21.36 |
| 12:14 ET | 2716 | 21.41 |
| 12:16 ET | 685 | 21.435 |
| 12:18 ET | 3554 | 21.395 |
| 12:20 ET | 500 | 21.41 |
| 12:21 ET | 200 | 21.4 |
| 12:23 ET | 200 | 21.42 |
| 12:25 ET | 900 | 21.42 |
| 12:27 ET | 2000 | 21.46 |
| 12:30 ET | 1200 | 21.445 |
| 12:32 ET | 1200 | 21.46 |
| 12:34 ET | 1816 | 21.45 |
| 12:36 ET | 1448 | 21.46 |
| 12:38 ET | 3768 | 21.49 |
| 12:39 ET | 1400 | 21.49 |
| 12:41 ET | 1469 | 21.49 |
| 12:43 ET | 5376 | 21.45 |
| 12:45 ET | 4345 | 21.4 |
| 12:48 ET | 6138 | 21.38 |
| 12:50 ET | 7559 | 21.46 |
| 12:52 ET | 3790 | 21.41 |
| 12:54 ET | 11729 | 21.45 |
| 12:56 ET | 9476 | 21.385 |
| 12:57 ET | 7442 | 21.35 |
| 12:59 ET | 111798 | 21.3 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Denali Therapeutics Inc | 3.1B | -22.0x | --- |
MorphoSys AG | 2.7B | -5.4x | --- |
Arrowhead Pharmaceuticals Inc | 3.1B | -5.9x | --- |
Amicus Therapeutics Inc | 2.9B | -19.9x | --- |
Genmab A/S | 16.4B | 21.1x | +22.71% |
Twist Bioscience Corp | 2.8B | -14.3x | --- |
Company Information
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates. Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS). In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome).
Contact Information
- Headquarters
- 161 Oyster Point BlvdSOUTH SAN FRANCISCO, CA, United States 94080-1910
- Phone
- 650-866-8548
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Vicki Sato
- President, Chief Executive Officer, Director
- Ryan Watts
- Chief Financial Officer, Chief Operating Officer, Company Secretary
- Alexander Schuth
- Chief Medical Officer
- Carole Ho
- Director
- Steven Krognes
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.1B |
|---|---|
Revenue (TTM) | $295.4M |
Shares Outstanding | 142.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.39 |
EPS | $-0.97 |
Book Value | $7.45 |
P/E Ratio | -22.0x |
Price/Sales (TTM) | 10.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -65.54% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
